【摘要】：研究背景 肝臟疾患是影響人類生活質(zhì)量和生命健康的重要疾病之一。不管其病因如何，這些疾病都將逐漸發(fā)展，演變?yōu)楦卫w維化或肝硬化，最終出現(xiàn)肝臟功能衰竭。對(duì)于各種類型的終末期肝病，肝移植在理論上應(yīng)該為最理想的治療選擇。但由于供體缺乏及保存供體的時(shí)間限制的原因，很多病人在等待肝移植的過(guò)程中即死亡。 生物人工肝系統(tǒng)能使終末期肝病病人橋接肝移植。肝細(xì)胞具有強(qiáng)大的再生能力，臨時(shí)應(yīng)用生物人工肝系統(tǒng)也可以解決急性肝功能的失代償，促進(jìn)肝細(xì)胞再生，肝功能可以暫時(shí)恢復(fù)，爭(zhēng)取到等待肝移植的時(shí)間。經(jīng)過(guò)幾十年的研究，生物人工肝系統(tǒng)已從非生物型、生物型人工肝系統(tǒng)發(fā)展到混合型人工肝系統(tǒng)，國(guó)內(nèi)外已經(jīng)有不少種類的人工肝系統(tǒng)應(yīng)用于臨床。肝細(xì)胞是生物人工肝系統(tǒng)的主要生物成分，，生物人工肝系統(tǒng)的支持作用主要來(lái)源于肝細(xì)胞的生物代謝功能。然而肝細(xì)胞不易在體外培養(yǎng)生長(zhǎng)，如何獲得高質(zhì)量、來(lái)源豐富的肝細(xì)胞是生物人工肝和干細(xì)胞移植面臨的共同問(wèn)題。 目前肝細(xì)胞來(lái)源主要是人源性肝細(xì)胞和動(dòng)物源性肝細(xì)胞，但都各有不同的缺陷。最為理想的是能在體外培養(yǎng)且保持肝細(xì)胞特性和功能的肝細(xì)胞，這種細(xì)胞必須具有合成代謝、解毒和生物轉(zhuǎn)化功能并能長(zhǎng)期存活，可以大量擴(kuò)增，解決
[Abstract]:Background liver disease is one of the most important diseases affecting the quality of life and health of human beings. Regardless of the etiology, these diseases develop gradually, leading to liver fibrosis or cirrhosis, and ultimately liver failure. For various types of end-stage liver disease, liver transplantation should theoretically be the best treatment option. However, due to the lack of donors and the time limit of donor preservation, many patients died while waiting for liver transplantation. The bioartificial liver system can bridge liver transplantation in patients with end-stage liver disease. The temporary application of bioartificial liver system can also solve the decompensation of acute liver function and promote the regeneration of liver cells. The liver function can be temporarily recovered and the time of waiting for liver transplantation can be obtained. After decades of research, bioartificial liver system has been developed from abiotic and biological artificial liver system to mixed artificial liver system. Many kinds of artificial liver system have been applied in clinic at home and abroad. Hepatocytes are the main biological components of the bioartificial liver system, and the supporting function of the bioartificial liver system is mainly derived from the biological metabolic function of the hepatocytes. However, it is difficult for hepatocytes to grow in vitro. How to obtain high quality and abundant hepatocytes is a common problem in bioartificial liver and stem cell transplantation. At present, the main sources of hepatocytes are human hepatocytes and animal derived hepatocytes, but they all have different defects. Ideally, hepatocytes that can be cultured in vitro and maintain the characteristics and functions of hepatocytes must have the functions of synthesis, detoxification and biotransformation, and can survive for a long time, and can be expanded in large quantities.
【學(xué)位授予單位】：第一軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2006
【分類號(hào)】：R329.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 申洪;免疫組織化學(xué)染色定量方法研究（Ⅲ）[J];中國(guó)組織化學(xué)與細(xì)胞化學(xué)雜志;1995年01期

2 唐望先,張國(guó),王俊平,張文英;流式細(xì)胞術(shù)動(dòng)態(tài)檢測(cè)肝大部切除后再生相關(guān)因子的實(shí)驗(yàn)研究[J];同濟(jì)醫(yī)科大學(xué)學(xué)報(bào);2001年04期

3 李玉昌,馬軍,林俊堂,梁衛(wèi)紅,徐存拴;大鼠短間隔連續(xù)部分肝切除后ADAMs mRNA表達(dá)分析[J];胃腸病學(xué)和肝病學(xué)雜志;2001年03期

4 唐佩弦;我國(guó)造血干細(xì)胞基礎(chǔ)研究的新進(jìn)展兼論干細(xì)胞可塑性(英文)[J];中國(guó)實(shí)驗(yàn)血液學(xué)雜志;2003年01期

5 舒朝鋒,崔磊,劉偉,曹誼林;人骨髓間充質(zhì)干細(xì)胞向軟骨細(xì)胞誘導(dǎo)分化的實(shí)驗(yàn)研究[J];中華創(chuàng)傷骨科雜志;2004年02期

6 羅依,梁彬,余勤;成人骨髓間充質(zhì)干細(xì)胞體外培養(yǎng)擴(kuò)增及其生物學(xué)特性研究[J];浙江醫(yī)學(xué);2003年08期

7 夏穗生;肝移植進(jìn)展[J];中國(guó)普外基礎(chǔ)與臨床雜志;2005年02期

本文編號(hào)：2307099